Measurement Specialties Stock Hits New 52-Week High (MEAS)

NEW YORK ( TheStreet) -- Measurement Specialties (Nasdaq: MEAS) hit a new 52-week high Wednesday as it traded at $33.39 compared with its previous 52-Week high of $33.27. Measurement Specialties is changing hands at $33.36 with 173,562 shares traded as of 3:10 p.m. ET. Average volume has been 97,000 shares over the past 30 days.

Measurement Specialties has a market cap of $476.8 million and is part of the technology sector and electronics industry. Shares are up 8.5% year to date as of the close of trading on Tuesday.

Measurement Specialties, Inc. engages in the design, development, and manufacture of sensors and sensor-based systems for original equipment manufacturers and end users. The company has a P/E ratio of 20.2, equal to the average electronics industry P/E ratio and above the S&P 500 P/E ratio of 16.1.
  • Practice your MEAS trading strategies and win cash in our stock game.

TheStreet Ratings rates Measurement Specialties as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Measurement Specialties Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing